US tax expense [Member] USTax Expense Member Schedule of Tax Losses [Line Items] Geographical areas [axis] Geographical areas [domain] Unused tax losses for which no deferred tax asset has been recognized Unused tax losses for which no deferred tax asset recognised Australian tax expense [Member] Australian Tax Expense Member Income Tax Expense - Schedule of Tax Losses (Details) [Table] Potential tax benefit Potential Tax Benefit The amount of unused tax losses potential tax benefit. Schedule Of Tax Losses Abstract Financial Assets and Financial Liabilities (Details) [Table] Accrued receivables Accrued Receivables Current The amount of accrued receivables. Potential tax benefit rate Potential Tax Benefit Rate Percentage of potential tax benefit rate. Schedule of Income Tax Expense [Abstract] Total current tax expense Current tax expense (income) and adjustments for current tax of prior periods Current assets Current assets [abstract] Cash and cash equivalents Balances per statement of cash flows Cash and cash equivalents Cash and cash equivalents at the beginning of the year Cash and cash equivalents at end of the year Cash and cash equivalents Schedule of Consolidated Statement of Cash Flows [Abstract] Schedule Of Trade And Other Receivables Abstract Trade and other receivables Current, Total Trade and other receivables Trade and other current receivables Trade and other receivables, Total Trade and other receivables Classes of financial assets [axis] Trade receivables [Member] Trade receivables [member] Other receivables [Member] Other Receivables Member Current tax on profits for the year Current tax expense (income) Income tax expense Income tax expense Income tax expense Tax expense (income) Schedule of Cash and Cash Equivalents [Abstract] Cash at bank and on hand Cash Trade and other receivables Non-Current, Total Trade and other non-current receivables Financial Assets and Financial Liabilities - Schedule of Trade and Other Receivables (Details) [Table] Classes of financial assets [domain] Accrued receivables [Member] Accrued Receivables Member Non-Financial Assets and Liabilities [Abstract] Financial Assets and Financial Liabilities [Line Items] Non-financial Assets and Liabilities [Line Items] Percentage of discount rate Discount rate used in current measurement of fair value less costs of disposal Income Tax Expense - Schedule of Tax Losses (Parentheticals) (Details) [Table] Balances as above Balances As Above Abstract Classes of liabilities [axis] Classes of liabilities [domain] Contingent Consideration [Member] Contingent consideration [member] Classes of financial instruments [domain] Diaprost Contingent Consideration [Member] Diaprost Contingent Consideration Member Pivalate Contingent Consideration [Member] Pivalate Contingent Consideration Member Pharma15 Contingent Consideration [Member] Pharma15 Contingent Consideration Member Advance Payment Liability [Member] Advance Payment Liability Member Schedule of Recurring Fair Value Measurements [Line Items] Total financial liabilities Financial liabilities Classes of intangible assets other than goodwill [axis] Provisions (in Dollars) Current Leave obligations Employee benefit obligations Current provisions for employee benefits MAb [Member] MAb Member Schedule Of Intangible Assets Abstract Sale of asset(note 6(a) Increase Decrease Through Other Than Goodwill Sale Of Asset It represents sale of asset. Amortization charge Increase (decrease) through other changes, intangible assets other than goodwill Closing net book amount Opening net book amount Net book amount Intangible assets Intangible assets other than goodwill Tranche 2 placement shares [Member] Tranche2 Placement Shares Member Issue of placement shares [Member] Issue Of Placement Shares Member Forfeiture shares [Member] Forfeiture Shares Member Milestone payments [Member] Milestone Payments Member Balance at beginning (in Shares) Balance at ending (in Shares) Ordinary shares Number of shares issued Issue of ordinary shares (in Shares) Issue Of Ordinary Shares Number of issue of ordinary shares. Transaction costs arising on share issues (in Shares) Transaction Costs Arising On Share Issues Number of shares issued transaction costs arising on share during issued. Equity - Schedule of Movements in Ordinary Shares (Parentheticals) (Details) [Table] Forfeiture shares as per employment contract [Member] Forfeiture Shares As Per Employment Contract Member Total Leave obligations Provisions for employee benefits Ordinary Shares [Abstract] Ordinary Shares Fully paid, shares Number of shares issued and fully paid Equity - Schedule of Movements in Ordinary Shares (Details) [Table] 2023-12-08 [Member] Two Thousand Twenty Three Twelve Zero Eight Member 2024-01-05 [Member] Two Thousand Twenty Four Zero One Zero Five Member 2024-02-09 [Member] Two Thousand Twenty Four Zero Two Zero Nine Member 2024-03-12 [Member] Two Thousand Twenty Four Zero Three Twelve Member 2024-05-16 [Member] Two Thousand Twenty Four Zero Five One Six Member 2024-08-21 [Member] Two Thousand Twenty Four Zero Eight Twenty One Member 2024-09-13 [Member] Two Thousand Twenty Four Zero Nine One Three Member 2024-12-16 [Member] Two Thousand Twenty Four Twelve Sixteen Member 2024-03-04 [Member] Two Thousand Twenty Four Zero Three Zero Four Member Tranche 2 placement shares [member] Tranche2 Placement Shares One Member Classes of ordinary shares [domain] Non-financial Assets and Liabilities - Schedule of Intangible Assets (Details) [Table] Exchange differences Increase (decrease) through net exchange differences, intangible assets other than goodwill Schedule of Employee Benefit Obligations [Abstract] Issue of securities [Member] Issue Of Securities Member Lantheus investment [Member] Lantheus Investment Member Achievement of a milestone [Member] Achievement Of AMilestone Member Issue of placement shares to Lantheus [Member] Issue Of Placement Shares To Lantheus Member Schedule of Movements in Ordinary Shares [Line Items] Balance at beginning Balance at ending Shares to be issued Issued capital, ordinary shares Issue of ordinary shares value Issue Of Ordinary Shares Value The amount of the issue of ordinary shares. Transaction costs arising on share issues value Transaction Costs Arising On Share Issues Value Represent the amount of transaction costs arising on share issues value. Issued capital [abstract] Classes of ordinary shares [axis] Pharma15 acquisition [Member] Pharma15 Acquisition Member Rights issue [Member] Rights Issue Member Lieu of cash for services rendered [Member] Lieu Of Cash For Services Rendered Member Lind agreement [Member] Lind Agreement Member Non- current Leave obligations Non-current provisions for employee benefits Ordinary shares Ordinary Shares Abstract Ordinary Shares Fully paid, value Ordinary Shares Fully Paid Amount of ordinary shares fully paid. Ordinary shares value Ordinary Shares Value Amount of ordinary shares. Creation date [axis] Issue of ordinary shares par value New per share Par value per share 2024-07-01 [Member] 2024-07-01 [Member] Two Thousand Twenty Four Zero Seven Zero One Member 2024-08-23 [Member] 2024-08-23 [Member] Two Thousand Twenty Four Zero Eight Twenty Three Member 2024-12-13 [Member] Two Thousand Twenty Four Twelve Thirteen Member 2025-01-20 [Member] Two Thousand Twenty Five Zero One Twenty Member Total other reserves [Member] Other reserves Other reserves [member] Beginning balance Ending balance Other reserves Other reserves Components of equity [axis] Other comprehensive loss Exchange differences on translation of foreign operations Other comprehensive income, net of tax, exchange differences on translation of foreign operations Issue of options as part of forfeiture payments Increase Decrease Through Issue Of Options As Part Of Forfeiture Payments The increase (decrease) in the entity's equity resulting from the issue of options as part of forfeiture payments. Issue of shares as part of forfeiture payments Increase Decrease Through Issue Of Shares As Part Of Forfeiture Payments The increase (decrease) in the entity's equity resulting from the issue of shares as part of forfeiture payments. Issue of options Processed amount Issue of equity Expiration of options Increase Decrease Through Expiration Of Options The increase (decrease) in equity resulting from the expiration of options. Components of equity [domain] Exchange difference Increase (decrease) through net exchange differences, investment property 2025-10-24 [Member] TwoThousandTwentyFiveTenTwentyFourMember [Member] 2025-12-05 [Member] TwoThousandTwentyFiveTwelveZeroFiveMember [Member] 2025-12-09 [Member] TwoThousandTwentyFiveTwelveZeroNineMember [Member] Default financial statements date [member] Pharma15 Corporation [Member] Pharma Fifteen Corporation Member Interests in Other Entities - Schedule of Summarized Balance Sheet (Details) [Table] Radiopharm Ventures LLC [Member] Radiopharm Ventures LLCMember Current assets Total current assets Current assets Current net assets Current assets (liabilities) Non-current net assets Noncurrent Net Assets Represents the amount of non-current net assets. Accumulated non-controlling interests Non-controlling interests Non-controlling interests Schedule Of Summarized Statement Of Comprehensive Loss Abstract Consolidated Entities [Axis] Schedule of Summarized Statement of Comprehensive Loss [Line Items] Place of business/country of incorporation Country of incorporation of subsidiary Ownership interest held by non-controlling interests Ownership Interest Held By Noncontrolling Interests Represents the percentage of ownership interest held by non-controlling interests. Total comprehensive loss Total comprehensive loss for the year Comprehensive income Total comprehensive income/(loss) for the year Comprehensive income Contingent Consideration - Schedule of Development Milestone Payments (Details) [Table] Financial instruments with cash flow risk Financial Instruments With Cash Flow Risk Abstract Financial Risk Management - Schedule of Impact of Interest Rate Risk (Details) [Table] Interest rate risk [member] Interest Rate Risk [Member] Interest rate risk [member] Impact on post-tax loss Impact On Posttax Loss Amount of impact on post-tax loss. Financial Risk Management - Schedule of Maturities of Financial Liabilities (Details) [Table] Maturity [domain] 6 - 12 months [Member] Not later than one year [member] Last patient Phase 3 (Therapeutic) [member] Last Patient Phase Three Therapeutic Member Equivalent of Either of These that is Sufficient to Allow Dosing in Humans in any Country in the Territory [Member] Equivalent Of Either Of These That Is Sufficient To Allow Dosing In Humans In Any Country In The Territory Member Last patient Phase 2B [member] Last Patient Phase Two BMember First patient Phase 2 [member] First Patient Phase Two Member Approval at first of FDA, EMA, PMDA for Diagnostic trials [member] Approval At First Of FDAEMAPMDAFor Diagnostic Trials Member IND allowance by the U.S. FDA or the EMA or the NMPA (for the PKT-7 Therapeutic) [member] INDAllowance By The USFDAOr The EMAOr The NMPAfor The PKT7 Therapeutic Member First patient dosed in the first Phase 2 therapeutic clinical trial [member] First Patient Dosed In The First Phase2 Therapeutic Clinical Trial Member Phase 1 clinical trial commencement limited to each of the 1st indication [member] Phase1 Clinical Trial Commencement Limited To Each Of The1st Indication Member Phase 3 clinical trial commencement limited to each of the 1st 3 indications [member] Phase3 Clinical Trial Commencement Limited To Each Of The1st3 Indications Member Grant of EU (or UK) Regulatory Approval [member] Grant Of EUor UKRegulatory Approval Member Aggregate Net Sales worldwide exceeding [member] Aggregate Net Sales Worldwide Exceeding Member Clearing of IND in the US or any country in Territory [member] Clearing Of INDIn The USOr Any Country In Territory Member IND allowance by the U.S. FDA or the EMA or the NMPA (for either the HER-2 or the TROP-2 Therapeutic) [member] INDAllowance By The USFDAOr The EMAOr The NMPAfor Either The HER2 Or The TROP2 Therapeutic Member First patient dosed in the first Phase 1 therapeutic clinical trial [member] First Patient Dosed In The First Phase One Therapeutic Clinical Trial Member First patient dosed in the first Phase 3 therapeutic clinical trial, or approval of a Licensed Product [member] First Patient Dosed In The First Phase3 Therapeutic Clinical Trial Or Approval Of ALicensed Product Member First patient dosed in the first Phase 3 therapeutic clinical trial [member] First Patient Dosed In The First Phase3 Therapeutic Clinical Trial Member Phase 2 clinical trial commencement limited to each of the 1st 3 indications [member] Phase2 Clinical Trial Commencement Limited To Each Of The1st3 Indications Member Grant of US Regulatory Approval [member] Grant Of USRegulatory Approval Member First commercial sale [member] First Commercial Sale Member Aggregate Net Sales worldwide exceeding [member] Aggregate Net Sales Worldwide Exceeding One Member Phase 1 clinical trial/pivotal study commencement, limited to each of the 1st indication [member] Phase1 Clinical Trialpivotal Study Commencement Limited To Each Of The1st Indication Member Phase 3 clinical trial/pivotal study commencement, limited to each of the 1st 3 indications [member] Phase3 Clinical Trialpivotal Study Commencement Limited To Each Of The1st3 Indications Member Any Marketing Approval in Japan, China, Hong Kong or the United States of (68Ga-TRIVEHEXIN) for diagnostic application (Diagnostic) [member] Any Marketing Approval In Japan China Hong Kong Or The United States Of68 Ga TRIVEHEXINFor Diagnostic Application Diagnostic Member First patient Phase 2 (Therapeutic) [member] First Patient Phase Two Therapeutic Member Initiation of Phase I Clinical Trial of a Licensed Product [member] Initiation Of Phase IClinical Trial Of ALicensed Product Member Initiation of Phase III Clinical Trial of a Licensed Product [member] Initiation Of Phase IIIClinical Trial Of ALicensed Product Member Regulatory Approval of a BLA for a Licensed Product by the FDA [member] Regulatory Approval Of ABLAFor ALicensed Product By The FDAMember Regulatory Approval of a BLA (or equivalent in a non-US jurisdiction) for a Licensed Product by the Japanese equivalent of the FDA [member] Regulatory Approval Of ABLAor Equivalent In ANon USJurisdiction For ALicensed Product By The Japanese Equivalent Of The FDAMember FDA submission [member] FDASubmission Member EMA approval [member] EMAApproval Member FDA IND allowance for a therapeutic product [member] FDAINDAllowance For ATherapeutic Product Member Products and services [domain] Interests in Other Entities [Line Items] Contingent Consideration (Details) [Table] Classes of contingent liabilities [domain] Deferred Payment [Member] Deferred Payment Member Intangible assets material to entity [domain] hu PSA Anti-body intellectual property [member] hu PSAAntibody Intellectual Property Member Pharma15 [Member] Pharma15 Member Range [axis] Top of range [member] Top of Range [Member] Top of range [Member] Top of range [member] Contingent Consideration [Line Items] Payment for development milestone Payment For Development Milestone To TRIMT Payment for development milestone to TRIMT. Payment of license agreement Payment Of License Agreement With Diaprost AB Payment of license agreement with Diaprost AB. Payment for development milestone Payment For Development Milestone To Diaprost AB Payment for development milestone to diaprost AB. Payment for development milestone Payment For Development Milestone To Nano Mab Payment for development milestone to nanomab. Payment for development milestone (in Euro) Payment For Development Milestone To CRT Payment for development milestone to CRT. Payment of license agreement Payment Of License Agreement With Pharma15 Payment of license agreement with pharma15. Beginning balance ,share Ending balance, share Share options Number of share options outstanding in share-based payment arrangement Issue of listed options, share (in Shares) Number Of Share Options Issue Oflisted Options Shares he number of share options issue of listed options, shares. Issue of unlisted options, shares Number Of Share Options Issue Of Unlisted Options Shares he number of share options issue of unlisted options, shares. Expiration of options, value Number Of Expiration Of Options Value Represent the amount of expiration of options value. Expense for share-based payments for options previously issued, value Expense from equity-settled share-based payment transactions Issue of ESOP unlisted options, shares Number Of Share Options Issue Of ESOPUnlisted Options Shares he number of share options issue of ESOP unlisted options. Forfeiture of options, share Number of options, Forfeited during the year Number of share options forfeited in share-based payment arrangement Total issue of other equity Other equity Total Other equity interest Schedule of Reconciliation of Profit After Income Tax to Net Cash Inflow From Operating Activities [Abstract] Adjustments for Adjustments For Abstract Schedule Of Other Equity Abstract Classes of share capital [axis] Consolidated Entities [Domain] Beginning balance, value Ending balance, value Number Of Outstanding Share Options Value Represent the amount of shares option for other reserves. Issue of listed options, value Issue Of Listed Options Value Issue of listed options, value. Expiration of options ,share Number of share options expired in share-based payment arrangement Expense for share-based payments for options previously issued, shares Number Of Share Options Expense For Sharebased Payments For Options Previously Issued Shares The number of share options expense for share-based payments for options previously issued. Issue of unlisted options, value Number Of Issue Of Unlisted Options Value Represent the amount of issue of unlisted options. Issue of ESOP unlisted options, value Number Of Issue Of ESOPUnlisted Options Value Represent the amount of issue of ESOP unlisted options, value. Forfeiture of options, value Number Of Forfeiture Of Options Value Represent the amount of forfeiture of options value. Schedule of Other Equity [Line Items] Loss for the year Loss for the year Profit (loss) Equity - Schedule of Other Equity (Details) [Table] Classes of share capital [domain] Share-based payments Share-based payments expenses Adjustments for share-based payments Depreciation and amortization Adjustments for depreciation and amortisation expense Finance costs Adjustments for finance costs Leave provision Adjustments for provisions Movement in other current assets Adjustments for decrease (increase) in other current assets Net cash outflow from operating activities Net cash outflows from operations Net cash payments from operating activities Cash flows from (used in) operating activities Schedule Of Exposure To Foreign Currency Risk Abstract Between 2 and 5 years [Member] Between2 And5 Years Member Schedule of Maturities of Financial Liabilities [Line Items] Impairment Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss Change in operating assets and liabilities: Change In Operating Assets And Liabilities Abstract Total non-derivatives Nonderivatives Amount of non-derivatives. Schedule Of Group SSubsidiaries Abstract Subsidiaries [axis] Other financial liabilities Other financial liabilities, Total Other financial liabilities Schedule Of Statement Of Financial Position Line Item Other Reserves And The Movements In These Reserves During The Year And Period Abstract Share-based payments [Member] Share Based Payments Member Schedule Of Movements In Options Abstract Types of antidilutive instruments [axis] Schedule of Movements in Options [Line Items] Shares to be issued Shares To Be Issued Shares to be issued. Financial Risk Management - Schedule of Impact of Foreign Currency Risk (Details) [Table] USD/AUD [Member] USDAUDMember GBP/AUD [Member] GBPAUDMember Financial Risk Management - Schedule of Impact of Foreign Currency Risk (Parentheticals) (Details) [Table] Exchange rate Exchange Rate Exchange rate. Schedule Of Exposure To Interest Rate Risk Abstract Types of risks [axis] Schedule of Exposure to Foreign Currency Risk [Line Items] Schedule of Exposure to Interest Rate Risk [Line Items] Financial instruments with cash flow risk Financial Instruments With Cash Flow Risk Amount of financial instrument with cash flow risk. Schedule Of Impact Of Interest Rate Risk Abstract Anderson for any other licenced product [member] Anderson For Any Other Licenced Product Member Pivalate intellectual property [member] Pivalate Intellectual Property Member Categories of related parties [axis] NanoMab Technology Limited [member] Nano Mab Technology Limited Member Schedule of Development Milestone Payments [Line Items] Material Estimates and Judgements (Details) [Table] Reduction in time frame for completion of clinical trials Reduction In Timeframe For Completion Of Clinical Trials It represents reduction in time frame for completion of clinical trials. Development period Services And Development Period It represents services over the expected development period. Contingent Consideration - Schedule of Commercialization Payments (Parentheticals) (Details) [Table] Total Key management personnel compensation Schedule Of Transactions With Key Management Personal Abstract Forfeiture payments expense to key management personnel [Member] Forfeiture Payments Expense To Key Management Personnel Member Schedule of Transactions with Key Management Personnel [Line Items] Schedule of Transactions with Key Management Personal [Line Items] Short-term employee benefits Key management personnel compensation, short-term employee benefits Long-term benefits Key management personnel compensation, other long-term employee benefits Weighted average exercise price per share option, Granted during the year Weighted average exercise price of share options granted in share-based payment arrangement Weighted average exercise price per share option, Forfeited during the year Weighted average exercise price of share options forfeited in share-based payment arrangement Weighted average exercise price per share option, Ending balance Weighted average exercise price per share option, Beginning balance Weighted average exercise price of share options outstanding in share-based payment arrangement Weighted average exercise price per share option, Vested and exercisable Weighted Average Exercise Price Per Share Option Vested And Exercisable The weighted average exercise price of share options vested exercisable in a share-based payment arrangement. Share-Based Payments - Schedule of Share Options Outstanding (Details) [Table] 01/08/2025 [Member] Zero One Zero Eight Two Thousand And Twenty Five [Member] Share-Based Payments - Schedule of Employee Option Plan (Details) [Table] Employee Option Plan [Member] Employee Option Plan Member Schedule of Model Inputs for Options Granted [Line Items] Exercise price ($) (in Dollars per share) Exercise price, share options granted 20/11/2025 [Member] Twenty Eleven Two Thousand And Twenty Five [Member] Research and development expenses Research and development Research and development expense Gain/(loss) on movement in contingent consideration Gains (losses) on change in fair value of derivatives Finance expenses Finance costs Other comprehensive income/(loss) Schedule of Other Income [Abstract] Diluted loss per share (in Dollars per share) Diluted earnings (loss) per share Statement of financial position [abstract] Owners of Radiopharm Theranostics Limited Comprehensive income, attributable to owners of parent Basic loss per share (in Dollars per share) Basic earnings (loss) per share Property, plant and equipment Property, plant and equipment Total assets Assets Trade and other payables Trade and other payables, Current Trade and other current payables Other current assets Net current assets Other current assets Trade and other payables Trade and other payables, Non- current Trade and other non-current payables Total non-current liabilities Non-current liabilities Non-current liabilities Net assets Assets (liabilities) Share capital Issued capital Issued capital Total current liabilities Current liabilities Current liabilities Current liabilities Segment Information [Abstract] Revenue from contract with customers Disclosure of revenue from contracts with customers [text block] Financial assets and financial liabilities Disclosure of redesignated financial assets and liabilities [text block] Equity Disclosure of share capital, reserves and other equity interest [text block] Other Income and Expense Items [Abstract] Income tax expense Disclosure of income tax [text block] Document Fiscal Year Focus Amendment Flag Title of 12(b) Security General and administrative expenses General and administrative expenses General and administrative expense Operating loss Profit (loss) from operating activities Loss before income tax Loss from continuing operations before income tax expense Profit (loss) before tax Total comprehensive loss for the year is attributable to: Comprehensive income attributable to [abstract] Non-controlling interests Loss allocated to non-controlling interests Comprehensive income, attributable to non-controlling interests Loss per share for loss attributable to the ordinary equity holders of the group: Loss Per Share [Abstract] Non-current assets Non-current assets [abstract] Total non-current assets Non-current assets Non-current assets Current liabilities Current liabilities [abstract] Non-current liabilities Non-current liabilities [abstract] Other financial liabilities Other financial liabilities, Non- current Other non-current financial liabilities Total liabilities Liabilities EQUITY Shareholders’ equity Equity [abstract] Other financial liabilities Other financial liabilities, Current Other current financial liabilities Deferred revenue Deferred income including contract liabilities Net (Decrease)/Increase in cash and cash equivalents Increase (decrease) in cash and cash equivalents before effect of exchange rate changes Effects of exchange rate changes on cash and cash equivalents Effect of exchange rate changes on cash and cash equivalents Segment information Disclosure of operating segments [text block] Revenue from Contract with Customers [Abstract] Accumulated losses Accumulated other comprehensive income Total equity Balance Balance Total shareholders’ equity Equity Consolidated Statement Of Changes In Equity Abstract Non-financial assets and liabilities Disclosure of offsetting of financial assets and financial liabilities [text block] Equity [Abstract] Reserves Other income and expense items Disclosure of other operating income (expense) [text block] Income Tax Expense [Abstract] Financial Risk Management [Abstract] Capital management Disclosure Of Capital Management Explanatory The disclosure of capital management. Interests in Other Entities [Abstract] Cash flow information Disclosure Of Cash Flow Information Explanatory The disclosure of cash flow information. Material Estimates and Judgements [Abstract] Contingent consideration Disclosure of contingent liabilities [text block] Commitments [Abstract] Share-Based Payments Disclosure of share-based payment arrangements [text block] Remuneration of Auditors [Abstract] Other equity Other equity interest [member] Accumulated losses Retained earnings [member] Other comprehensive income Other comprehensive income, before tax Revenue from contracts with customers Contracts with customers Revenue from contracts with customers Gross Profit Gross profit Other losses Total Other expense, by function Contributions of equity Issue Of Equity Gross Issue of equity, gross before deducting transaction costs. Contributions of equity net of transaction costs Increase (decrease) through transactions with owners, equity Issue of shares for milestone completion Issue Of Shares For Milestone Completion The amount of issue of shares for milestone completion. Expiry date Number Of Options Granted Expiry Date The options granted for expired date. No. of options Option life, share options granted Schedule of Expenses Arising from Share-Based Payment Transactions [Abstract] Remuneration of Auditors - Schedule of Payable for Services by the Auditor (Details) [Table] Audit and review of financial statements [Member] Audit And Review Of Financial Statements Member Total remuneration for audit and other assurance services [Member] Total Remuneration For Audit And Other Assurance Services Member Expected volatility Expected volatility, share options granted Risk-free interest rate Risk free interest rate, share options granted Auditor Location Cover [Abstract] Document Information [Line Items] Document Registration Statement Document Financial Statement Error Correction [Flag] Document Shell Company Report Document Period End Date Document Fiscal Period Focus Entity Common Stock, Shares Outstanding Security Exchange Name Related Party Transactions [Abstract] Schedule of Reconciliation of Profit After Income Tax to Net Cash Inflow From Operating Activities Disclosure of profit (loss) from operating activities [text block] Schedule of Impact of Foreign Currency Risk Schedule Of Impact Of Foreign Currency Risk Table Text Block The disclosure of impact of foreign currency risk table text block. Summary of Material Accounting Policies [Abstract] Schedule of Impact of Interest Rate Risk Schedule Of Impact Of Interest Rate Risk Table Text Block The disclosure of impact of interest rate risk table text block. Assets classified as held for sale Description Of Accounting Policy For Assets Or Disposal Groups Classified As Held For Sale Explanatory The description of the entity's material accounting policy information for assets or disposal groups classified as held for sale. Classification and measurement of financial liabilities Description of accounting policy for financial liabilities [text block] Trade and other payables Description of accounting policy for trade and other payables [text block] Loss per share Description of accounting policy for earnings per share [text block] Accounting Policies [Abstract] Principles of consolidation Disclosure of basis of consolidation [text block] Impairment of assets Description of accounting policy for impairment of assets [text block] Schedule of Revenue from Contract with Customers Disclosure of disaggregation of revenue from contracts with customers [text block] Schedule of Information on Major Customers Disclosure of major customers [text block] Entity Registrant Name ICFR Auditor Attestation Flag Entity Voluntary Filers Entity Filer Category Entity Shell Company Entity Ex Transition Period Entity Incorporation, State or Country Code Entity Addresses, Address Type [Axis] Business Contact Business Contact [Member] Entity Address, Address Line Two Entity Address, Postal Zip Code Local Phone Number Contact Personnel Name Trading Symbol Schedule of Payable for Services by the Auditor [Line Items] Basic loss per share from continuing operations Basic earnings (loss) per share from continuing operations Weighted average number of ordinary shares used as the denominator in calculating basic loss per share Weighted average number of ordinary shares used in calculating basic earnings per share Classes of financial instruments [axis] Parent Entity Financial Information - Schedule of Financial Statements (Details) [Table] Parent [Member] Parent [member] Statement of financial position Assets [abstract] Guarantees Guarantees Represents the amount of guarantees. Summary of Material Accounting Policies (Details) [Table] Summary of Material Accounting Policies [Line Items] Auditor [Line Items] Auditor Firm ID Auditor Opinion [Text Block] Entity [Domain] Categories of related parties [domain] Loss per share Disclosure of earnings per share [text block] Parent Entity Financial Information [Abstract] Related party transactions Disclosure of related party [text block] Cash Flow Information [Abstract] Cash flows from operating activities Schedule of Exposure to Foreign Currency Risk Disclosure of effect of changes in foreign exchange rates [text block] Summary of material accounting policies Disclosure of material accounting policy information [text block] Events Occurring After the Reporting Year [Abstract] Schedule of Exposure to Interest Rate Risk Schedule Of Exposure To Interest Rate Risk Table Text Block The disclosure of exposure to interest rate risk table text block. Schedule of Maturities of Financial Liabilities Schedule Of Maturities Of Financial Liabilities Table Text Block The disclosure of maturities of financial liabilities table text block. Contributed equity Description of accounting policy for issued capital [text block] Revenue recognition Description of accounting policy for recognition of revenue [text block] Basis of preparation Description Of Accounting Policy For Basis Of Preparation Explanatory The description of the entity's material accounting policy information for basis of preparation. Foreign currency translation Description of accounting policy for foreign currency translation [text block] Schedule of Information on Geographical Regions Disclosure of geographical areas [text block] Entity Central Index Key Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Current Reporting Status Entity File Number Entity Emerging Growth Company Address Type [Domain] Entity Address, Address Line One Entity Address, City or Town Entity Address, Country City Area Code Contact Personnel Email Address Total auditors’ remuneration Auditor's remuneration Schedule of Reconciliations of Loss Used in Calculating Loss Per Share [Abstract] Diluted loss per share from continuing operations Diluted earnings (loss) per share from continuing operations Schedule of Weighted Average Number of Shares Used as the Denominator [Abstract] Weighted average number of ordinary shares used as the denominator in calculating diluted loss per share Weighted average number of ordinary shares used in calculating diluted earnings per share Audit and other assurance services [Member] Audit And Other Assurance Services Member Schedule of Financial Statements [Line Items] Schedule Of Financial Statements Abstract Contractual commitments Contractual capital commitments Going concern [Member] Going Concern Member Maximum overdue days Maximum Overdue Days Maximum overdue days. Auditor Name Types of share-based payment arrangements [domain] Transactions with owners in their capacity as owners: Transactions with owners in their capacity as owners Transactions with owners in their capacity as owners [Abstract] Impairment – Pharma 15 Impairment on Other Equity Amount of Impairment on other equity. 2025-07-01 [Member] One Zero Seven Two Thousand Twenty Five [Member] 2025-08-01 [Member] One Zero Eight Two Thousand Twenty Five [Member] 2025-11-20 [Member] Twenty Eleven Two Thousand Twenty Five [Member] 2026-06-01 [Mmeber] One Zero Six Two Thousand Twenty Six [Member] 2025-12-09 [Member] Nine Twelve Two Thousand Twenty Five [Member] Disclosure of non-adjusting events after reporting period [table] Non-adjusting events after reporting period [axis] Non-adjusting events after reporting period [domain] Events occurring after the reporting year [line items] Disclosure of non-adjusting events after reporting period [line items] Events After Reporting Period [Member] Institutional offer Amount Used Amount of institutional offer. Amount of Institutional Offer Amount of institutional offer. Amount of Institutional Launched Amount of institutional launched. United States [Member] UNITED STATES Schedule of Model Inputs for Options Granted Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block] Schedule of Payable for Services by the Auditor Schedule Of Payable For Services By The Auditor Text Block The disclosure of schedule of payable for services by the auditor. Revenue from Contract with Customers - Schedule of Information on Major Customers (Details) [Table] Employee leave obligations Tax Effect Of Employee Leave Obligations The amount that represents the difference between the tax expense (income) employee leave obligations. Patent costs Tax Effect Of Patent Costs The amount that represents the difference between the tax expense (income) patent costs. Unrealized currency movements Tax Effect Of Unrealized Currency Movements The amount that represents the difference between the tax expense (income) unrealized currency movements. Tax losses and other timing differences for which no deferred tax asset is recognized Other tax effects for reconciliation between accounting profit and tax expense (income) Customer A [Member] Customer AMember Research and Development tax incentive Research And Developments Tax Incentive Research and development tax incentive received. Schedule Of Breakdown Of Expenses By Nature Abstract Attribution of expenses by nature to their function [axis] Accounting and audit [Member] Accounting And Audit Member Depreciation [Member] Depreciations [Member] Insurance [Member] Insurance Member Fair value adjustment on financing agreements Adjustments for fair value losses (gains) Loss on sale of available-for-sale assets Gains on disposals of property, plant and equipment Patent costs [Member] Patent Costs Member Other [Member] Other Member AVb6 Integrin (TRIMT) [Member] AVb6 Integrin TRIMTMember Legal [Member] Legal Member Impairment [Member] Impairment Member NanoMab [Member] Nano Mab Member UCLA [Member] UCLAMember hu PSA Anti-body (Diaprost) [Member] hu PSAAntibody Diaprost Member Schedule of Development Milestone Payments Disclosure Of Development Milestone Payments Explanatory The disclosure of development milestone payments. Schedule of Key Management Personnel Compensation Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [text block] Schedule of Summarized Balance Sheet Schedule Of Summarized Balance Sheet Text Block The disclosure of schedule of summarized balance sheet. Schedule of Employee Option Plan Disclosure of number and weighted average exercise prices of share options [text block] Schedule of Weighted Average Number of Shares Used as the Denominator Disclosure Of Weighted Average Number Of Shares Used As The Denominator Explanatory Text Block Disclosure of weighted average number of shares used as the denominator. Schedule Of Information On Geographical Regions Abstract Schedule of Information on Geographical Regions [Line Items] Schedule of Expenses Arising from Share-Based Payment Transactions Disclosure of expenses [text block] Schedule Of Information On Major Customers Abstract Major customers [axis] Unrealized currency (gains)/losses Tax Effect Of Unrealised Currencygainslosses The amount of unrealised currency (gains)/losses. Share-based payments Tax Effect Of Sharebased Payments The amount that represents the difference between the tax expense (income) share-based payments. Subtotal Tax effect from change in tax rate Schedule of Information on Major Customers [Line Items] Other Income and Expense Items - Schedule of Breakdown of Expenses by Nature (Details) [Table] Attribution of expenses by nature to their function [domain] Consulting [Member] Consulting Member Employee benefits [Member] Employee Benefit [Member] Total Other income Other income Schedule of Other Losses [Abstract] Net foreign exchange gains/(losses) Foreign exchange gain (loss) Travel and entertainment [Member] Travel And Entertainment Member Tax at the rate Applicable tax rate Income Tax Expense - Schedule of Numerical Reconciliation of Income Tax Expense to Prima Facie Tax Payable (Parentheticals) (Details) [Table] Schedule Of Numerical Reconciliation Of Income Tax Expense To Prima Facie Tax Payable Abstract Schedule of Numerical Reconciliation of Income Tax Expense to Prima Facie Tax Payable [Line Items] Schedule of Intangible Assets [Line Items] Accumulation amortization and impairment Amortisation, intangible assets other than goodwill Non-financial Assets and Liabilities (Details) [Table] Probability of default [domain] Schedule Of Financial Liabilities With Significant Estimation Uncertainty Abstract Schedule Of Trade And Other Payables Abstract Trade payables [Member] Trade Payables Member Accrued expenses [Member] Accrued Expenses Member R&D advance [Member] RDAdvance Member Trade and other payables, Total Trade and other payables Schedule Of Other Financial Liabilities Abstract Categories of financial liabilities [axis] NeoIndicate Contingent Consideration [Member] Neo Indicate Contingent Consideration Member Pharma15 Deferred Consideration [Member] Pharma15 Deferred Consideration Member TRIMT Contingent Consideration [Member] TRIMTContingent Consideration Member MD Anderson Contingent Consideration [Member] MDAnderson Contingent Consideration Member Schedule of Other Financial Liabilities [Line Items] Financial Assets and Financial Liabilities - Schedule of Financial Liabilities with Significant Estimation Uncertainty (Details) [Table] NanoMab Contingent Consideration [Member] Nano Mab Contingent Consideration Member Financial Liabilities Financial Liabilities Abstract Impairment charge Impairment loss recognised in profit or loss, intangible assets other than goodwill Cost Increase (decrease) in investment property Financial Assets and Financial Liabilities - Schedule of Trade and Other Payables (Details) [Table] Amounts due to employees [Member] Amounts Due To Employees Member Other payables [Member] Other Payables Member Schedule of Trade and Other Payables [Line Items] Financial Assets and Financial Liabilities - Schedule of Other Financial Liabilities (Details) [Table] Categories of financial liabilities [domain] UCLA Contingent Consideration [Member] UCLAContingent Consideration Member Advanced Payment Liability [Member] Advanced Payment Liability Member Schedule of Trade and Other Receivables [Line Items] Probability of default [axis] AVb6 Integrin [Member] AVb6 Integrin Member Probability directors’ assumptions Percentage On Probability On Directors Assumption Percentage on probability of director's assumptions. Accrued leave or require payment Full Amount Of Accrued Leave Or Require Payment It represents employees full amount of accrued leave or require payment . Classes of intangible assets other than goodwill [domain] hu PSA Anti-body [Member] hu PSAAntibody Member Pivalate [Member] Pivalate Member Amortized over a period Remaining amortisation period of intangible assets material to entity 2023-12-14 [Member] Two Thousand Twenty Three Twelve Month Fourteen Days Member 2024-01-31 [Member] Two Thousand Twenty Four Zero One Thirty One Member 2024-04-15 [Member] Two Thousand Twenty Four Zero Four One Five Member 2024-02-14 [Member] Two Thousand Twenty Four Zero Two One Four Member Classes of property, plant and equipment [domain] Classes of property, plant and equipment [axis] Rights issue shortfall [Member] Rights Issue Shortfall Member Other Intellectual Property [Member] Other Intellectual Property Member 2025-06-12 [Member] Two Thousand Twenty Five Zero Six Twelve Member Schedule of Movements in Ordinary Shares [Line Items] Equity Scheduleof Movementsin Ordinary Shares Parentheticals Details Line Items Foreign currency translation [Member] Foreign Currency Translation Member Schedule of Statement of Financial Position Line Item ‘Other Reserves’ and the Movements in These Reserves During the Year and Period [Line Items] Equity - Schedule of Statement of Financial Position Line Item ‘Other Reserves’ and the Movements in These Reserves During the Year and Period (Details) [Table] Equity settled payments [Member] Equity Settled Payments Member Issue of shares as part of placement Increase Decrease Through Issue Of Shares As Part Of Placement The increase (decrease) in the entity's equity resulting from the issue of shares as part of placement. Cancellation of shares to be issued relating to Lind Cancellation of treasury shares Currency translation differences Gains (losses) on exchange differences on translation of foreign operations, net of tax Forfeiture of options Increase Decrease Through Forfeiture Of Options The increase (decrease) in equity resulting from the forfeiture of options. Phase 2 clinical trial/pivotal study commencement, limited to each of the 1st 3 indications [member] Phase2 Clinical Trialpivotal Study Commencement Limited To Each Of The1st3 Indications Member Grant of MA in the EU (or UK) [member] Grant Of MAIn The EUor UKMember Commencement of Phase 3 diagnostic clinical trial for (68Ga-TRIVEHEXIN) (Diagnostic) [member] Commencement Of Phase3 Diagnostic Clinical Trial For68 Ga TRIVEHEXINDiagnostic Member Last patient Phase 1 (Therapeutic) [member] Last Patient Phase One Therapeutic Member Last patient Phase 2 (Therapeutic) [member] Last Patient Phase Two Therapeutic Member Initiation of Phase II Clinical Trial of a Licensed Product [member] Initiation Of Phase IIClinical Trial Of ALicensed Product Member Filing of BLA (or equivalent in a non-US jurisdiction) for a Licensed Product [member] Filing Of BLAor Equivalent In ANon USJurisdiction For ALicensed Product Member Regulatory Approval of a BLA (or equivalent in a non-US jurisdiction) for a Licensed Product by the European Union equivalent of the FDA [member] Regulatory Approval Of ABLAor Equivalent In ANon USJurisdiction For ALicensed Product By The European Union Equivalent Of The FDAMember Upon the dosing of the final patient in a Pivotal Study [member] Upon The Dosing Of The Final Patient In APivotal Study Member Owned subsidiary Ownership interest held by the group Proportion of ownership interest in subsidiary Contingent Consideration [Abstract] Classes of contingent liabilities [axis] Intangible assets material to entity [axis] AVb6 Integrin intellectual property [member] AVb6 Integrin Intellectual Property Member NanoMab intellectual property [member] Nano Mab Intellectual Property Member Range [domain] Bottom of range [member] Bottom of Range [Member] Bottom of range [Member] Bottom of range [member] Payment of license agreement Payment Of License Agreement With TRIMT Payment of license agreement with TRIMT. Payments for milestones Payments For Milestones Payments for milestones. Cash paid Portion of consideration paid (received) consisting of cash and cash equivalents Payment of license agreement Payment Of License Agreement With Nano Mab Technology LTD Payment of license agreement with nanomab technology limited. Payment of license agreement (in Euro) Payment Of License Agreement With CRT Payment of license agreement with CRT. Payment for development milestone Payment For Development Milestone To Radiopharm Ventures LLC Payment for development milestone to radiopharm ventures LLC. Payment for development milestone Payment For Development Milestone To Pharma15 Payment for development milestone to Pharma15. Types of antidilutive instruments [domain] Schedule Of Summarized Balance Sheet Abstract Schedule of Summarized Balance Sheet [Line Items] Interests in Other Entities - Schedule of Summarized Statement of Comprehensive Loss (Details) [Table] Schedule of Group’s Subsidiaries [Line Items] Schedule Of Development Milestone Payments Abstract Schedule of Impact of Interest Rate Risk [Line Items] Impact on other components of equity Impact On Other Components Of Equity Amount of impact on other components of equity. Schedule Of Maturities Of Financial Liabilities Abstract Maturity [axis] Less than 6 months [Member] Not Later Than Six Months Member First patient Phase 3 (Therapeutic) [member] First Patient Phase3 Therapeutic Member Any Marketing Approval in the Territory other than in Australia (Therapeutic) [member] Any Marketing Approval In The Territory Other Than In Australia Therapeutic Member Trade payables Trade payables First patient Pivotal Study [member] First Patient Pivotal Study Member Last patient Phase 1 [member] Last Patient Phase One Member Second indication, approval at first of FDA, EMA, PMDA [member] Second Indication Approval At First Of FDAEMAPMDAMember Contingent issue of equity [Member] Contingent Issue Of Equity Member Disposal of intellectual property Adjustments for losses (gains) on disposal of non-current assets Contingent consideration Adjustments for decrease (increase) in financial assets held for trading Finance income Adjustments for finance income Movement in trade receivables Adjustments for decrease (increase) in trade and other receivables Movement in trade payables Adjustments for increase (decrease) in trade and other payables Between 1 and 2 years [Member] Between1 And2 Years Member Over 5 years [Member] Over5 Years Member Net foreign currency (gains)/losses Adjustments for unrealised foreign exchange losses (gains) Total Contractual Maturities Of Financial Liabilities Amount of contractual maturities of financial liabilities. Interests in Other Entities - Schedule of Group’s Subsidiaries (Details) [Table] Radiopharm Theranostics (USA) Inc [Member] Radiopharm Theranostics USAInc Member Shares to be issued [Member] Shares To Be Issued Member Transfer from Share-based payments to equity settled payments Transfer From Sharebased Payments To Equity Settled Payments Transfer from Share-based payments to equity settled payments. Lapse of forfeiture payment Increase Decrease Through Lapse Of Forfeiture Payment The increase (decrease) in the entity's equity resulting from the lapse of forfeiture payment. Equity - Schedule of Movements in Options (Details) [Table] Total exposure Maximum exposure to credit risk Schedule Of Impact Of Foreign Currency Risk Abstract Currency [Axis] EUR/AUD [Member] EURAUDMember Schedule of Impact of Foreign Currency Risk [Line Items] Financial Risk Management - Schedule of Exposure to Interest Rate Risk (Details) [Table] Financial Risk Management - Schedule of Exposure to Foreign Currency Risk (Details) [Table] Foreign Currency Risk [Member] Currency risk [member] FDA approval [member] FDAApproval Member Regulatory Approval of a BLA (or equivalent in a non-US jurisdiction) for a Licensed Product by the Chinese equivalent of the FDA [member] Regulatory Approval Of ABLAor Equivalent In ANon USJurisdiction For ALicensed Product By The Chinese Equivalent Of The FDAMember Products and services [axis] Therapeutic development [member] Therapeutic Development Member Anderson for Licenced products that target B7-H3 and/or are covered by B7-H3 patent rights [member] Anderson For Licenced Products That Target BSeven HThree Andor Are Covered By BSeven HThree Patent Rights Member PMDA approval [member] PMDAApproval Member Milestone payment Milestonepayment Represent the amount of milestone payments. Milestone payment Mile Stone Payments It represents amount of payment related to milestones. Discount rate Actuarial assumption of discount rates Cost of sales Cost of sales Cost of sales Financial Risk Management (Details) [Table] Foreign operations whose functional currency is not exchangeable into presentation currency [domain] Euro [Member] Euro Member Financial Risk Management [Line Items] Exposed interest rate risk Exposed Interest Rate Risk Exposed interest rate risk. Average change to cash interest rate risk Average Change To Cash Interest Rate Risk Average change to cash interest rate risk. Capital Management [Abstract] Material Estimates and Judgements [Line Items] Interests in Other Entities (Details) [Table] Radiopharm [Member] Radiopharm Member Date of options are granted Date of grant of share-based payment arrangement All Currencies [Domain] Types of risks [domain] Subsidiaries [domain] Revenue Total revenue from continuing operations Revenue Prepayments Prepayments Foreign operations whose functional currency is not exchangeable into presentation currency [axis] USD [Member] USDMember GBP [Member] GBPMember Exposed foreign exchange risk percentage Exposed Foreign Exchange Risk Percentage Exposed foreign exchange risk percentage. Average cash interest rate risk Average Cash Interest Rate Risk Percentage Average cash interest rate risk. Dividends paid Dividends recognised as distributions to owners MD Anderson [Member] MDAnderson Member Ownership of the joint venture Proportion of ownership interest in joint venture Probability on clinical trial success Percentage Of Probability On Clinical Trial Success It represents percentage of probability on clinical trial success. Trade receivables Franking account balance Franking Account Balance Franking account balance. IND submission to the U.S. FDA or the EMA or the NMPA for PDL-1 Therapeutic) – binding license agreement with a third-party to improve Camelid PDL-1 therapeutic index [Member] IND submission to the U.S. FDA or the EMA or the NMPA for PDL-1 Therapeutic) - IND submission for the Camelid PDL-1 New Formulation [Member] Statement of changes in equity [table] Share capital Issued capital [member] Non-controlling interests Non-controlling interests [member] Statement of changes in equity [line items] Profit or Loss [Abstract] Issue of shares as part of license acquisition Increase Decrease In Shares As Part Of License Acquisition Increase (decrease) in shares as part of license acquisition. Transaction costs Share issue related cost Issue of options Issue of convertible instruments Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Management, Strategy, and Governance [Table] CRT [Member] Cancer Research Technology Limited Member License fee payable Licence fee income Payable in cash Amount Payable In Cash Amount payable in cash. Loans to related parties Transfers Under Loans From Entity Related Party Transaction Transfers under loans from entity related party transaction. Upon total worldwide Net Sales of all Licensed Products exceeding [Member] Upon Total Worldwide Net Sales Of All Licensed Products Exceeding Three Member Contingent Consideration - Schedule of Commercialization Payments (Parentheticals) (Details) [Line Items] Contingent Consideration - Schedule of Commercialization Payments (Details) [Line Items] Financial risk management Disclosure of financial risk management [text block] Material estimates and judgements Disclosure of accounting judgements and estimates [text block] Commitments Disclosure of commitments and contingent liabilities [text block] Interests in other entities Disclosure of interests in other entities [text block] Share-Based Payments [Abstract] Remuneration of auditors Disclosure of auditors' remuneration [text block] Parent entity financial information Disclosure of basis of preparation of financial statements [text block] Equity-settled payments Increase (decrease) through share-based payment transactions, equity Forfeiture of options Options Forfeited Options forfeited. Increase in ownership in RAD Ventures Increase In Ownership In RADVentures Increase in ownership in RAD Ventures. Receipts from customers (inclusive of GST) Receipts from sales of goods and rendering of services Interest received Interest received, classified as operating activities Issue of shares in lieu of services Issue Of Shares In Lieu Of Services Issue of shares in lieu of services. Share issue transaction costs Payments for share issue costs Transaction costs related to loans and borrowings Payments for debt issue costs Settlement with Lind Settlement With Lind The amount of settlement with lind. Events occurring after the reporting year Explanation of financial effect of non-adjusting event after reporting period [text block] Receipts for sale of intellectual property Payments For Intellectual Property Payments for intellectual property. Cash flows from financing activities Cash flows from (used in) financing activities [abstract] Cash and cash equivalents Description of accounting policy for determining components of cash and cash equivalents [text block] Options issued Expense from share-based payment transactions Schedule Of Payable For Services By The Auditor Abstract Legal Entity [Axis] Audit of NASDAQ registration [Member] Audit Of NASDAQRegistration Member Share price at grant date ($) (in Dollars per share) Weighted average share price, share options granted Dividend yield Expected dividend as percentage, share options granted Fair value at grant date ($) (in Dollars) Fair Value At Grant Date The amount of fair value at grant date. Document Information [Table] Document Type Entity Interactive Data Current Document Annual Report Document Transition Report Document Accounting Standard Cancellation of shares to be issued Cancellation Of Shares To Be Issued The amount of cancellation of shares to be issued. Changes in equity Increase (decrease) in equity Payments to suppliers and employees (inclusive of GST) Payments to suppliers for goods and services and to and on behalf of employees Research and development tax incentive received Research And Development Tax Incentive Received Research and development tax incentive received. Cash flows from investing activities Cash flows from (used in) investing activities [abstract] Issue of shares per the share purchase agreement Increase (decrease) through treasury share transactions, equity Proceeds from borrowings Proceeds from borrowings, classified as financing activities Repayment of borrowings Repayments of current borrowings Net cash proceeds from financing activities Cash flows from (used in) financing activities Payments for license fee liabilities Payments For License Fee Liabilities The amount of payments for license fee liabilities. Net cash (payments)/proceeds from investing activities Cash flows from (used in) investing activities Proceeds from issues of shares Proceeds from issuing shares Trade receivables Description of accounting policy for trade and other receivables [text block] Investments and other financial assets Description Of Accounting Policy Investments And Other Financial Assets Explanatory The description of the entity's material accounting policy information for investments and other financial assets. Intangible assets Description of accounting policy for intangible assets and goodwill [text block] Commitments (Details) [Table] Cybersecurity Risk Management, Strategy, and Governance [Abstract] Commitments [Line Items] Key management personnel forfeiture payments Key Management Personnel Forfeiture Payments Key management personnel, forfeiture payments. Payments to director related entities Payments To Director Related Entities Payments to director related entities. Loans Amounts payable, related party transactions Cybersecurity Risk Management, Strategy, and Governance [Line Items] Upon total worldwide Net Sales of all Licensed Products exceeding [Member] Upon Total Worldwide Net Sales Of All Licensed Products Exceeding One Member Upon total worldwide Net Sales of all Licensed Products exceeding [Member] Upon Total Worldwide Net Sales Of All Licensed Products Exceeding Five Member Net sales of all licensed products exceeding value Net Sales Of All Licensed Products Exceeding Value Net sales of all licensed products exceeding value. Upon total worldwide Net Sales of all Licensed Products exceeding Commercialization Payment Commercialization payment. Schedule Of Commercialization Payments Abstract Related Party Transactions - Schedule of Transactions with Key Management Personal (Details) [Table] Payments to director related entities [Member] Payments To Director Related Entities Member Transactions occurred with key management personnel Transactions Occurred With Key Management Personnel The amount of transactions occurred with key management personnel. Post-employment benefits Key management personnel compensation, post-employment benefits Share-based payments Key management personnel compensation, share-based payment Schedule Of Employee Option Plan Abstract Number of options, Granted during the year Number of share options granted in share-based payment arrangement Number of options, Ending balance (in Shares) Number of options, Beginning balance (in Shares) Number Of Shares Employee Option Plan Number of shares in the employee option plan. Number of options, Vested and exercisable Number Of Options Vested And Exercisable The number of share options vested and exercisable in a share-based payment arrangement. Schedule Of Share Options Outstanding Abstract 01/07/2025 [Member] Zero One Zero Seven Two Thousand And Twenty Five [Member] Types of share-based payment arrangements [axis] Schedule of Employee Option Plan [Line Items] 09/12/2025 [Member] 2025-01-30 [Member] Zero Nine Twelve Two Thousand Twenty Five [Member] Schedule of Consolidated Statement of Cash Flows Disclosure of cash flow statement [text block] Schedule of Trade and Other Payables Disclosure of trade and other payables [text block] Schedule of Financial Liabilities with Significant Estimation Uncertainty Disclosure of fair value measurement [text block] Schedule of Other Losses Disclosure Of Other Losses Table Text Block The tabular disclosure of other losses. Schedule of Numerical Reconciliation of Income Tax Expense to Prima Facie Tax Payable Disclosure Of Numerical Reconciliation Of Income Tax Expense To Prima Facie Tax Payable Explanatory The disclosure of numerical reconciliation of income tax expense to prima facie tax payable. Schedule of Income Tax Expense Disclosure Of Income Tax Expense Explanatory The disclosure of income tax expense. Schedule of Share Capital Disclosure of classes of share capital [text block] Schedule of Statement of Financial Position Line Item ‘Other Reserves’ and the Movements in These Reserves During the Year and Period Disclosure of reserves within equity [text block] Schedule of Other Equity Disclosure Of Other Equity Explanatory The disclosure of other equity. Schedule of Intangible Assets Disclosure of detailed information about intangible assets [text block] GrantDateDomain [Domain] 2021-04-05 [Member] Two Thousand And Twenty One Zero Four Zero Five Member 2021-06-27 [Member] Two Thousand And Twenty One Zero Six Twenty Seven Member 2021-08-02 [Member] Two Thousand And Twenty One Zero Eight Zero Two Member 2022-03-02 [Member] Two Thousand Twenty Two Zero Three Zero Two Member Upon total worldwide Net Sales of all Licensed Products exceeding [Member] Upon Total Worldwide Net Sales Of All Licensed Products Exceeding Two Member 2022-11-16 [Member] Two Thousand Twenty Two Eleven Sixteen Member 2023-02-07 [Member] Two Thousand Twenty Three Zero Two Zero Seven Member 2023-06-01 [Member] Two Thousand Twenty Three Zero Six Zero One Member 2023-07-24 [Member] Two Thousand Twenty Three Zero Seven Twenty Four Member 2023-12-13 [Member] Two Thousand Twenty Three Twelve Thirteen Member 2022-07-01 [Member] Two Thousand Twenty Two Zero Seven Zero One Member 2024-11-25 [Member] Twenty Five Eleven Two Thousand Twenty Four Member 2021-09-13 [Member] Two Thousand And Twenty One Zero Nine Thirteen Member 2023-11-14 [Member] Two Thousand Twenty Three Eleven Fourteen Member 2024-08-28 [Member] Twenty Eight Zero Eight Two Thousand And Twenty Fours Member Defined benefit plans [domain] Defined benefit plans [axis] Share-Based Payments - Schedule of Model Inputs for Options Granted (Details) [Table] Equity Settled Payments Reserve of gains and losses from investments in equity instruments Schedule of Share Options Outstanding [Line Items] Exercise price (in Dollars per share) Exercise price of outstanding share options Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Schedule of Other income Disclosure Of Other Income Table Text Block The tabular disclosure of other income. Schedule of Breakdown of Expenses by Nature Disclosure of expenses by nature [text block] Schedule of Cash and Cash Equivalents Disclosure of cash and cash equivalents [text block] Schedule of Trade and Other Receivables Disclosure of trade and other receivables [text block] Schedule of Other Financial Liabilities Disclosure of financial liabilities [text block] Schedule of Tax Losses Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Schedule of Movements in Ordinary Shares Disclosure of issued capital [text block] Schedule of Movements in Options Disclosure Of Movements In Options Explanatory The disclosure of movements in options. Schedule of Employee Benefit Obligations Disclosure of defined benefit plans [text block] Contingent Consideration - Schedule of Commercialization Payments (Details) [Table] Upon total worldwide Net Sales of all Licensed Products exceeding [Member] Upon Total Worldwide Net Sales Of All Licensed Products Exceeding Member Grant Date [Axis] Grant Date Axis 2021-03-29 [Member] Two Thousand And Twenty One Zero Three Twenty Nine Member 2021-04-26 [Member] Two Thousand And Twenty One Zero Four Twenty Six Member 2021-07-28 [Member] Two Thousand And Twenty One Zero Seven Twenty Eight Member 2021-12-21 [Member] Two Thousand And Twenty One Twelve Twenty One Member Upon total worldwide Net Sales of all Licensed Products exceeding [Member] Upon Total Worldwide Net Sales Of All Licensed Products Exceeding Four Member 2022-11-16 [Member] Two Thousand Twenty Two Eleven Sixteen One Member 2023-05-18 [Member] Two Thousand Twenty Three Zero Five Eighteen Member 2023-07-01 [Member] Two Thousand Twenty Three Zero Seven Zero One Member 2023-11-16 [Member] Two Thousand Twenty Three Eleven Sixteen Member 2024-06-01 [Member] Two Zero Two Four Zero Six Zero One Member 2022-04-22 [Member] Two Thousand Twenty Two Zero Four Twenty Two Member 2024-11-25 [Member] Twenty Five Eleven Two Thousand Twenty Fours Member 2022-11-25 [Member] Two Thousand And Twenty Two Eleven Twenty Five Member 2024-02-06 [Member] Two Thousand And Twenty Four Zero Two Zero Six Member OIP Plan [Member] OIPPlan Member Share Options [Member] Share options [member] Weighted average remaining contractual life of options outstanding at end of year Weighted average remaining contractual life of outstanding share options Schedule Of Model Inputs For Options Granted Abstract Share-based payments Reserve of share-based payments Expiry date Expiry Date Of Outstanding Share Options The expiry date of outstanding share options. Retained earnings Retained earnings Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Management Third Party Engaged [Flag] Ordinary shares [Member] Ordinary shares [member] Plan [Axis] Plans name [Domain] Share Purchase Plan [Member] Underlying ordinary shares Underlying ordinary shares. Underlying ordinary shares price per share Underlying ordinary shares price per share. ADS [Member] American Depositary Share [Member] Subsequent Events [Member] Accrued expenses Tax effect of tax losses Number of reportable segment Number Of Reportables Segments Number of reportable segments. Other Income and Expense Items (Details) [Table] Other Income and Expense Items [Line Items] Research and development prior year rebate Research And Development Prior Years Rebate It represents research and development prior year rebate. Research and Development tax incentive Other income research and development Tax Effect Of Research And Development Tax Incentive The amount that represents the difference between the tax expense (income) research and development tax incentive. Schedule of Reconciliations of Loss Used in Calculating Loss Per Share Earnings per share [text block] Tax rate Tax expense (income) at applicable tax rate Accounting expenditure subject to R&D tax incentive Tax Effect Of Accounting Expenditure Subject To Researchand Development Tax Incentive The amount that represents the difference between the tax expense (income) accounting expenditure subject to R&D tax incentive. Amortization Tax Effect Of Tax Amortisation The amount of amortisation. Revenues percent Percentage of entity's revenue Research and Development [Member] Research And Development Member Schedule of Summarized Statement of Comprehensive Loss Schedule Of Summarized Statement Of Comprehensive Loss Text Block The disclosure of schedule of summarized statement of comprehensive loss. Schedule of Commercialization Payments Disclosure of products and services [text block] Schedule of Transactions with Key Management Personnel Disclosure of transactions between related parties [text block] Schedule of Group’s Subsidiaries Disclosure of subsidiaries [text block] Schedule of Share Options Outstanding Disclosure of range of exercise prices of outstanding share options [text block] Schedule of Financial Statements Disclosure of general information about financial statements [text block] Schedule of Revenue from Contract with Customers [Abstract] Revenue from Contract with Customers - Schedule of Information on Geographical Regions (Details) [Table] Amortization [Member] Amortization Member Investor relations [Member] Investor Relations Member Listing and share registry [Member] Listing And Share Registry Member R&D Ventures [Member] RDVentures Member Neoindicate [Member] Neoindicate Member Pivalate - Imperial [Member] Pivalate Imperial Member Schedule of Breakdown of Expenses by Nature [Line Items] Consulting Fees R&D [Member] Consulting Fees RDMember Income Tax Expense - Schedule of Numerical Reconciliation of Income Tax Expense to Prima Facie Tax Payable (Details) [Table] Major customers [domain] Australia [Member] AUSTRALIA Tax effect of amounts which are not deductible/(taxable) in calculating taxable income: Tax effect of amounts which are not deductible/(taxable) in calculating taxable income [Abstract] Interest Income Amount of interest income. Federal tax rate Pecentage of Federal Tax Rate Pecentage of federal tax rate. New york state rate Percentage of New York State Rate Percentage of new york state rate.